KRW 13990.0
(-1.82%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 52.79 Billion KRW | -21.59% |
2022 | 67.32 Billion KRW | -16.39% |
2021 | 80.52 Billion KRW | -14.09% |
2020 | 93.74 Billion KRW | 48.24% |
2019 | 63.23 Billion KRW | 17.08% |
2018 | 54 Billion KRW | 9.11% |
2017 | 49.49 Billion KRW | -7.27% |
2016 | 53.38 Billion KRW | 22.96% |
2015 | 43.41 Billion KRW | 32.33% |
2014 | 32.8 Billion KRW | 6.37% |
2013 | 30.84 Billion KRW | -3.8% |
2012 | 32.06 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 105.7 Billion KRW | 96.73% |
2024 Q1 | 53.73 Billion KRW | 1.78% |
2023 Q4 | 52.79 Billion KRW | -13.24% |
2023 FY | 52.79 Billion KRW | -21.59% |
2023 Q1 | 65.6 Billion KRW | -2.55% |
2023 Q2 | 62.08 Billion KRW | -5.36% |
2023 Q3 | 60.84 Billion KRW | -2.0% |
2022 Q4 | 67.32 Billion KRW | -14.95% |
2022 Q1 | 78.23 Billion KRW | -2.85% |
2022 Q2 | 73.33 Billion KRW | -6.26% |
2022 Q3 | 79.16 Billion KRW | 7.94% |
2022 FY | 67.32 Billion KRW | -16.39% |
2021 Q3 | 92.75 Billion KRW | -3.12% |
2021 FY | 80.52 Billion KRW | -14.09% |
2021 Q1 | 94.17 Billion KRW | 0.46% |
2021 Q2 | 95.73 Billion KRW | 1.66% |
2021 Q4 | 80.52 Billion KRW | -13.18% |
2020 Q4 | 93.74 Billion KRW | -3.08% |
2020 FY | 93.74 Billion KRW | 48.24% |
2020 Q2 | 64.38 Billion KRW | 4.88% |
2020 Q1 | 61.38 Billion KRW | -4.42% |
2020 Q3 | 96.72 Billion KRW | 50.23% |
2019 Q3 | 65.21 Billion KRW | 1.46% |
2019 FY | 63.23 Billion KRW | 17.08% |
2019 Q4 | 64.22 Billion KRW | -1.52% |
2019 Q2 | 64.27 Billion KRW | -0.05% |
2019 Q1 | 64.3 Billion KRW | 19.07% |
2018 Q1 | 50.03 Billion KRW | 1.09% |
2018 FY | 54 Billion KRW | 9.11% |
2018 Q4 | 54 Billion KRW | 5.45% |
2018 Q3 | 51.21 Billion KRW | -0.26% |
2018 Q2 | 51.35 Billion KRW | 2.64% |
2017 Q4 | 49.49 Billion KRW | -4.59% |
2017 FY | 49.49 Billion KRW | -7.27% |
2017 Q1 | 49.91 Billion KRW | -6.5% |
2017 Q2 | 49.19 Billion KRW | -1.44% |
2017 Q3 | 51.88 Billion KRW | 5.47% |
2016 FY | 53.38 Billion KRW | 22.96% |
2016 Q2 | 46.39 Billion KRW | -0.25% |
2016 Q3 | 55.17 Billion KRW | 18.94% |
2016 Q4 | 53.38 Billion KRW | -3.26% |
2016 Q1 | 46.5 Billion KRW | 7.13% |
2015 Q3 | 35.36 Billion KRW | 3.52% |
2015 Q4 | 43.41 Billion KRW | 22.77% |
2015 Q2 | 34.16 Billion KRW | -9.22% |
2015 Q1 | 37.62 Billion KRW | 14.7% |
2015 FY | 43.41 Billion KRW | 32.33% |
2014 Q2 | 29.04 Billion KRW | -7.3% |
2014 Q3 | 31.06 Billion KRW | 6.94% |
2014 Q1 | 31.33 Billion KRW | 1.6% |
2014 Q4 | 32.8 Billion KRW | 5.61% |
2014 FY | 32.8 Billion KRW | 6.37% |
2013 FY | 30.84 Billion KRW | -3.8% |
2013 Q1 | 31.1 Billion KRW | -2.98% |
2013 Q2 | 26.31 Billion KRW | -15.39% |
2013 Q4 | 30.84 Billion KRW | -4.03% |
2013 Q3 | 32.13 Billion KRW | 22.11% |
2012 FY | 32.06 Billion KRW | 0.0% |
2012 Q4 | 32.06 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Sam Chun Dang Pharm. Co., Ltd | 408.02 Billion KRW | 87.062% |
ST Pharm Co.,Ltd. | 686.83 Billion KRW | 92.314% |
ABL Bio Inc. | 160.14 Billion KRW | 67.035% |
Cellid, Co., Ltd. | 63.92 Billion KRW | 17.413% |